# Schrodinger, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Schrodinger, Inc.).

## Overview

Schrodinger, Inc. develops computational software used to model molecules and support drug discovery for biopharmaceutical companies, academic researchers, and selected materials science users. The company also pursues proprietary drug discovery programs that use the same physics-based platform to identify and optimize new therapeutic candidates.

## Products & services

• Computational software for drug discovery
• Molecular modeling and simulation platform
• Software licenses for commercial and academic users
• Drug discovery collaboration programs
• Proprietary therapeutic programs

- **Software solutions** (70%) — Computational tools used to accelerate molecule discovery, design, and optimization.
- **Drug discovery collaborations** (25%) — Partner-funded discovery programs with milestones, research funding, and related services.
- **Professional services** (3%) — Ad hoc scientific and technical services supporting customer deployments and workflows.
- **Software contribution revenue** (2%) — Non-reciprocal funding tied to specific platform expansion initiatives.

- Computational software for drug discovery
- Molecular modeling and simulation platform
- Software licenses for commercial and academic users
- Drug discovery collaboration programs
- Proprietary therapeutic programs

## Customers

Schrodinger sells primarily to pharmaceutical and biotechnology companies that use its software to speed early-stage research and improve decision-making in discovery programs. It also serves academic institutions worldwide and a growing set of materials science customers that use the platform for simulation and design workflows.

- **Large pharmaceutical companies** (primary) — Buy enterprise software licenses to support target identification, design, and optimization across discovery teams.
- **Biotechnology companies** (primary) — Use the platform for discovery workflows and to access advanced modeling capabilities without building them internally.
- **Academic institutions** (secondary) — Use the software for research and training, helping broaden adoption and scientific familiarity.
- **Materials science customers** (emerging) — Apply the platform to simulation and design problems outside life sciences.
- **Drug discovery collaborators** (secondary) — Provide research funding and milestone-based payments for partnered therapeutic programs.

- Large pharmaceutical companies buying enterprise software licenses
- Biotechnology companies using tools for early discovery workflows
- Academic institutions using the platform for research and teaching
- Materials science customers applying simulation to non-pharma problems
- Collaboration partners funding proprietary drug discovery programs

## Geography

Schrodinger operates globally, with direct sales coverage across the United States, the European Union, the United Kingdom, Japan, India, and South Korea. It also uses distributors in other markets, including China, which broadens reach but adds cross-border commercial and regulatory complexity.

- United States is a core commercial market and operating base
- Europe and the UK support pharma customer access and academic adoption
- Japan, India, and South Korea extend direct sales coverage in Asia
- China is served partly through distributors rather than direct sales
- Global customer base supports both software and collaboration revenue

## Strategy

Schrodinger’s strategy is to expand adoption of its computational platform across drug discovery and adjacent scientific markets while deepening usage within large pharma accounts. It also advances proprietary drug discovery programs selectively, using partnerships, out-licensing, or internal development where appropriate to maximize value from its platform and pipeline.

- **Grow software penetration in large pharma and biotech** (short-term) — Enterprise adoption drives recurring license revenue and expands platform usage across discovery teams.
- **Broaden use cases beyond life sciences** (medium-term) — Materials science expands the addressable market and reduces dependence on drug discovery alone.
- **Advance proprietary programs through partnerships** (medium-term) — Partnerships can fund development and reduce capital intensity while preserving upside.

- Expand software adoption across pharma, biotech, academia, and materials science
- Increase usage within existing customers through broader platform deployment
- Use partnerships to advance proprietary drug discovery programs
- Selectively out-license or co-develop assets to monetize pipeline value
- Maintain global sales and scientific support to drive customer retention

## Risks

The business depends on retaining and expanding a relatively concentrated base of pharmaceutical customers, so competitive displacement or lower renewal rates would pressure software growth. Its proprietary drug discovery efforts also carry scientific, regulatory, and financing risk, while international operations expose the company to cross-border execution and compliance challenges.

- **Customer retention and expansion risk** [high] — A meaningful share of software revenue comes from a limited number of large commercial accounts, so churn or downsizing would affect recurring revenue.
- **Competition from AI and internal discovery platforms** [high] — Pharma companies can build tools internally or adopt alternative AI-based discovery solutions.
- **Clinical and preclinical program failure** [high] — Proprietary assets depend on scientific success, regulatory progress, and partner interest.
- **International operating risk** [medium] — Global sales, distributors, and cross-border customers create legal, tax, and execution complexity.
- **Capital needs and dilution risk** [high] — The company may need external financing to support software development and drug discovery activities.

- Customer concentration in large pharma can amplify renewal and expansion risk
- Competition from AI drug discovery and internal tools may reduce demand
- Drug discovery programs may fail scientifically or take longer than expected
- International sales and distributor channels add compliance and execution risk
- Additional capital may be needed to fund software and pipeline investment

## Accounting

Revenue recognition is a key accounting area because the company sells software licenses, professional services, collaboration arrangements, and contribution-funded programs with different timing rules. Drug discovery revenue depends on milestone probability, progress estimates, and variable consideration, while software arrangements may be recognized over the contract term and can create quarter-to-quarter timing swings.

- **Revenue recognition for software and collaborations** — Software licenses, collaboration milestones, and contribution funding
- **Variable consideration and progress measurement** — Drug discovery revenue timing
- **Fair value measurement of equity investments** — Other income (expense)
- **Quarterly revenue timing** — Period-to-period comparability

- Software licenses may be recognized over the contract term
- Collaboration revenue depends on milestone probability and progress estimates
- Variable consideration and standalone selling price judgments affect revenue allocation
- Contribution revenue is recognized under not-for-profit accounting rules
- Fair value changes in equity investments can affect other income

---

*Last updated: 2026-04-29T04:57:42.198827+00:00*